Skip to main
  1. Stocks
  2. Illumina
  3. Forecast
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 36%
Hold 21%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is viewed favorably because its clinical sequencing franchise is inflecting, with oncology-led demand, improving reimbursement, and repeated catalysts in MRD, tumor profiling, colorectal cancer blood tests, and multi-cancer detection supporting durable mid-teens growth. The company also appears well positioned to defend and expand share through a leading cost basis, high consumables gross margins above 70%, strong instrument demand for NovaSeq X, and sticky customer relationships that raise switching costs in clinical workflows. Beyond core sequencing, BioInsight could add a new growth vector through licensing or subscriptions, while the market’s premium valuation is supported by stronger sales acceleration and a path to margin leverage as new products scale.

Bears say

Illumina is facing a fundamentally challenged demand backdrop, as clinical growth may not be sustainable, academic spending remains weak, and research and applied sequencing consumables ex-China are expected to decline in 2026. Its core economics are under pressure from customer-driven deflation in per-sample unit economics, while the shift from NovaSeq 6000 to NovaSeq X is weighing on core revenue, consumables revenue, instrument margins, and overall gross margins. At the same time, China risk remains elevated because the company is still on the unreliable entities list, sales there have fallen from 10% a few years ago to about 5% of 2026 sales, and intensified competition from Roche, MGI, private firms, and long-read peers threatens share.

Illumina (ILMN) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Illumina (ILMN) Analyst Forecast & Price Prediction

Get the latest Illumina (ILMN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Illumina (ILMN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 14 analysts, Illumina (ILMN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $262.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $262.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Illumina (ILMN) Analyst Forecast & Price Prediction

Get the latest Illumina (ILMN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Illumina (ILMN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ILMN stock data and trends